Top-Rated StocksTop-Rated Axonics Stock Price, News & Analysis (NASDAQ:AXNX) $57.23 -0.65 (-1.12%) (As of 02:16 PM ET) Add Compare Share Share Today's Range$57.09▼$58.3150-Day Range$49.38▼$59.1452-Week Range$47.59▼$68.93Volume239,830 shsAverage Volume632,416 shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$71.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Axonics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside24.7% Upside$71.60 Price TargetShort InterestHealthy4.26% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment0.85Based on 5 Articles This WeekInsider TradingSelling Shares$436,477 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.20) to $0.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector90th out of 960 stocksSurgical & Medical Instruments Industry14th out of 74 stocks 3.5 Analyst's Opinion Consensus RatingAxonics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $71.60, Axonics has a forecasted upside of 24.7% from its current price of $57.44.Amount of Analyst CoverageAxonics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.26% of the outstanding shares of Axonics have been sold short.Short Interest Ratio / Days to CoverAxonics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Axonics has recently decreased by 22.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxonics does not currently pay a dividend.Dividend GrowthAxonics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxonics has received a 59.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Incontinence medication", "Implants and prostheses", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Axonics is -1.38. Previous Next 3.2 News and Social Media Coverage News SentimentAxonics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Axonics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for AXNX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added Axonics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axonics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $436,477.00 in company stock.Percentage Held by InsidersOnly 1.85% of the stock of Axonics is held by insiders.Percentage Held by Institutions99.00% of the stock of Axonics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axonics are expected to grow in the coming year, from ($0.20) to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axonics is -229.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axonics is -229.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxonics has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axonics Stock (NASDAQ:AXNX)Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Read More AXNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXNX Stock News HeadlinesDecember 4, 2023 | finance.yahoo.comWhen Will Axonics, Inc. (NASDAQ:AXNX) Become Profitable?December 3, 2023 | americanbankingnews.comAxonics (NASDAQ:AXNX) Trading Up 3.5%December 8, 2023 | Edge On The Street (Ad)Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.December 1, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Short Interest Down 22.0% in NovemberDecember 1, 2023 | americanbankingnews.comAxonics, Inc. (NASDAQ:AXNX) Given Consensus Rating of "Buy" by BrokeragesNovember 20, 2023 | finance.yahoo.comWall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to TradeNovember 7, 2023 | finance.yahoo.comAxonics (NASDAQ:AXNX) delivers shareholders solid 29% CAGR over 5 years, surging 8.0% in the last week aloneNovember 1, 2023 | finance.yahoo.comAxonics to Participate in November Investor ConferencesDecember 8, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. October 30, 2023 | sfgate.comAxonics: Q3 Earnings SnapshotOctober 30, 2023 | finance.yahoo.comAxonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top EstimatesOctober 30, 2023 | finance.yahoo.comAxonics Inc (AXNX) Reports 32% YoY Revenue Growth in Q3 2023October 30, 2023 | finance.yahoo.comAxonics Reports Third Quarter 2023 Financial ResultsOctober 23, 2023 | finance.yahoo.comAxonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 11, 2023 | finance.yahoo.comUnveiling Axonics (AXNX)'s True Worth: A Comprehensive Guide to Its Market ValueOctober 9, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Castle Biosciences (CSTL), Axonics Modulation Technologies (AXNX) and Apellis Pharmaceuticals (APLS)October 2, 2023 | finance.yahoo.comAxonics to Report Third Quarter 2023 Financial Results on October 30September 22, 2023 | finance.yahoo.comUnveiling Axonics (AXNX)'s Value: Is It Really Priced Right? A Comprehensive GuideSeptember 11, 2023 | finance.yahoo.comAxonics (AXNX): A Significantly Undervalued Gem in the Medical Technology Sector?September 7, 2023 | seekingalpha.comAxonics: Growing Duopolist With Superior Product And No DebtAugust 25, 2023 | finance.yahoo.comAxonics to Participate in September Investor ConferencesAugust 21, 2023 | finance.yahoo.comAxonics Announces CFO Retirement and Appoints SuccessorJuly 31, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Axonics Modulation Technologies (AXNX) and SAGE Therapeutics (SAGE)July 29, 2023 | seekingalpha.comAxonics: Rapid Growth But Waiting For ProfitabilityJuly 28, 2023 | markets.businessinsider.comAnalyst Ratings for AxonicsJuly 28, 2023 | finance.yahoo.comWhy Shares of Axonics Rose FridayJuly 28, 2023 | washingtonpost.comAxonics: Q2 Earnings SnapshotSee More Headlines Receive AXNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXNX CUSIPN/A CIK1603756 Webwww.axonics.com Phone(949) 396-6322Fax949-396-6321Employees610Year FoundedN/APrice Target and Rating Average Stock Price Target$71.60 High Stock Price Target$75.00 Low Stock Price Target$63.00 Potential Upside/Downside+23.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,700,000.00 Net Margins-3.50% Pretax Margin-4.10% Return on Equity-2.04% Return on Assets-1.82% Debt Debt-to-Equity RatioN/A Current Ratio13.36 Quick Ratio11.25 Sales & Book Value Annual Sales$273.70 million Price / Sales10.74 Cash FlowN/A Price / Cash FlowN/A Book Value$11.51 per share Price / Book5.04Miscellaneous Outstanding Shares50,660,000Free Float49,725,000Market Cap$2.94 billion OptionableNot Optionable Beta0.48 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Raymond W. Cohen (Age 64)CEO & Director Comp: $1.71MMr. Rinda K. Sama (Age 44)Chief Operating Officer Comp: $902.83kDr. John Woock Ph.D. (Age 40)Executive VP, Chief Marketing & Strategy Officer Comp: $902.83kMr. Alfred J. Ford Jr. (Age 52)Chief Commercial Officer Comp: $902.96kMs. Kari KeeseChief Financial OfficerMr. Guangqiang Jiang Ph.D. (Age 49)Chief Technology Officer Mr. Neil BhalodkarVice President of Investor RelationsMr. Aaron PettitGeneral Counsel & Chief Compliance OfficerMr. Michael V. Williamson Esq. (Age 51)J.D., Senior VP, General & IP Counsel Dr. Karen L. Noblett M.A.S. (Age 60)M.D., Chief Medical Officer Comp: $651.4kMore ExecutivesKey CompetitorsGlaukosNYSE:GKOSiRhythm TechnologiesNASDAQ:IRTCIntegra LifeSciencesNASDAQ:IARTCantel MedicalNYSE:CMDICU MedicalNASDAQ:ICUIView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 17,431 shares on 12/6/2023Ownership: 0.001%Deutsche Bank AGSold 48,747 shares on 11/24/2023Ownership: 0.179%Walleye Capital LLCSold 32,182 shares on 11/21/2023Ownership: 0.007%Comerica BankSold 9,368 shares on 11/21/2023Ownership: 0.001%Diversified Trust CoBought 1,625 shares on 11/17/2023Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions AXNX Stock Analysis - Frequently Asked Questions Should I buy or sell Axonics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXNX shares. View AXNX analyst ratings or view top-rated stocks. What is Axonics' stock price target for 2024? 10 brokerages have issued 1 year price targets for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they predict the company's stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 24.7% from the stock's current price. View analysts price targets for AXNX or view top-rated stocks among Wall Street analysts. How have AXNX shares performed in 2023? Axonics' stock was trading at $62.53 at the beginning of 2023. Since then, AXNX shares have decreased by 8.1% and is now trading at $57.44. View the best growth stocks for 2023 here. Are investors shorting Axonics? Axonics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, a decline of 22.0% from the October 31st total of 2,770,000 shares. Based on an average trading volume of 557,600 shares, the short-interest ratio is currently 3.9 days. View Axonics' Short Interest. When is Axonics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our AXNX earnings forecast. How were Axonics' earnings last quarter? Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Monday, October, 30th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.13. The business earned $93.10 million during the quarter, compared to analysts' expectations of $89.60 million. Axonics had a negative trailing twelve-month return on equity of 2.04% and a negative net margin of 3.50%. The business's revenue for the quarter was up 32.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS. What ETFs hold Axonics' stock? ETFs with the largest weight of Axonics (NASDAQ:AXNX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Nuveen Small Cap Select ETF (NSCS), Principal Healthcare Innovators ETF (BTEC) and Goldman Sachs Future Health Care Equity ETF (GDOC).iShares U.S. Medical Devices ETF (IHI). What guidance has Axonics issued on next quarter's earnings? Axonics issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $358.00 million-$358.00 million, compared to the consensus revenue estimate of $358.73 million. What is Raymond W. Cohen's approval rating as Axonics' CEO? 20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend. What other stocks do shareholders of Axonics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT). When did Axonics IPO? (AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers. Who are Axonics' major shareholders? Axonics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (9.00%), Bamco Inc. NY (3.55%), Invesco Ltd. (3.23%), Loomis Sayles & Co. L P (2.47%), Mackenzie Financial Corp (2.46%) and Artisan Partners Limited Partnership (1.26%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara. View institutional ownership trends. How do I buy shares of Axonics? Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AXNX) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axonics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.